Advances in Relapsed/Refractory Myeloma: Keeping Pace With a Rapidly Evolving Treatment Landscape

Download All
This online program is based on a live satellite symposium covering the latest therapeutic strategies for the management of relapsed/refractory multiple myeloma, including the latest clinical data on the safety and efficacy of emerging agents. Watch the on-demand webcast, download the slidesets from the satellite symposium, and read an expert commentary.
Paul G. Richardson, MD
Program Director
Natalie S. Callander, MD
Noopur Raje, MD

Downloadable Slidesets

Download these expert-selected slides on current best practices for early stage relapsed/refractory multiple myeloma to help diagnose and manage your patients.

Natalie S. Callander, MD Released: June 7, 2022

Download these expert-selected slides on current best practices for later-stage relapsed/refractory multiple myeloma and investigational agents in this setting.

Paul G. Richardson, MD
Program Director
Released: June 7, 2022

Download these expert-selected slides on current and investigational anti-BCMA CAR T-cell and bispecific therapies for relapsed/refractory multiple myeloma.

Noopur Raje, MD Released: June 7, 2022

On-Demand Webcast

In this on-demand webcast from a live symposium, Paul G. Richardson, MD; Natalie S. Callander, MD; and Noopur Raje, MD explore the latest advances in new and emerging therapies for patients with relapsed or refractory multiple myeloma.

Paul G. Richardson, MD
Program Director
Natalie S. Callander, MD Noopur Raje, MD
Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: June 8, 2022 Expired: June 7, 2023
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie Inc.
GlaxoSmithKline
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Karyopharm Therapeutics
Regeneron Pharmaceuticals, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings